Action Consortium

Home / Childhood Cancer / Funding Childhood Cancer Initiatives / ACTION

Our debut funding call is focused on refractory and relapse neuroblastoma, a hard-to-cure solid tumour cancer most often diagnosed in children.  The grant calls for innovative approaches to accelerating clinical trials and the evaluation of novel therapies. By pooling our resources to form the ACTION Consortium, this award will be one of the largest seen in the neuroblastoma field, standing at $2 million USD. Our aim is to challenge the scientific community to bring proposals with the potential to instil significant change to the neuroblastoma landscape, which will directly and positively impact children facing this devastating disease.

Kindred Foundation is honoured to partner with the ACTION Consortium to help push forward on the treatment of relapsed and refractory (hard-to-cure) neuroblastoma.  Funding from Kindred Foundation will ensure that the research and clinical trial that is ultimately funded by this grant will be implemented in Canada.  Canada plays a significant role in international childhood cancer research; however, far too often Canadian children do not get access to innovative clinical trials.  Kindred Foundation is funding the Canadian operations of this grant, providing $450,000 USD (~$600,000 CAD) over four years.

This feat of international collaboration has been born from the shared values and missions of our five organizations- to drive and invest in clinical research that addresses the areas of most unmet need within childhood cancer and bring better treatment to children as rapidly as possible. We are excited to be entering into this partnership for the benefit of children with neuroblastoma and look forward to seeing this award progress.

This grant call has been developed and funded by the ACTION Consortium and is being managed by Solving Kids’ Cancer UK on behalf of consortium partners.  For additional information, please see our one-page summary on the ACTION Grant (PDF).